When the combination of serum AFP and serum myostatin levels was used, patients with both high serum myostatin and high serum AFP levels had a significantly higher risk of HCC development than those with both low serum myostatin and low serum AFP levels. This evidence concerns the gene AFP and hepatocellular carcinoma.